Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.
Śledzińska A, Vila de Mucha M, Bergerhoff K, Hotblack A, Demane DF, Ghorani E, Akarca AU, Marzolini MAV, Solomon I, Vargas FA, Pule M, Ono M, Seddon B, Kassiotis G, Ariyan CE, Korn T, Marafioti T, Lord GM, Stauss H, Jenner RG, Peggs KS, Quezada SA. Śledzińska A, et al. Among authors: marzolini mav. Immunity. 2020 Jan 14;52(1):151-166.e6. doi: 10.1016/j.immuni.2019.12.007. Epub 2020 Jan 7. Immunity. 2020. PMID: 31924474 Free PMC article.
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor A, Jones C, Uttenthal B, Johnson R, Sanderson R, Cheok K, Marzolini M, Townsend W, O'Reilly M, Kirkwood AA, Kuhnl A. Roddie C, et al. Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019. Blood Adv. 2023. PMID: 36724512 Free PMC article.
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
Marzolini MAV, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, Pocock CFE, Miall F, Cunningham D, Stephens R, Walewski J, Johnston A, Seymour JF, Linch DC, Ardeshna KM. Marzolini MAV, et al. Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19918. Online ahead of print. Br J Haematol. 2024. PMID: 39604791
Trafficking of CAR T cells to sites of subclinical leukaemia cutis.
O'Reilly M, Roddie C, Marzolini MAV, Rodriguez-Justo M, Pomplun S, Pule M, Peggs KS. O'Reilly M, et al. Among authors: marzolini mav. Lancet Oncol. 2020 Mar;21(3):e179. doi: 10.1016/S1470-2045(19)30861-7. Lancet Oncol. 2020. PMID: 32135121 No abstract available.
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, Hartley JA, Spanswick V, Lowe H, Popova B, Clifton-Hadley L, Wheeler G, Olejnik J, Bloor A, Irvine D, Wood L, Marzolini MAV, Domning S, Farzaneh F, Lowdell MW, Linch DC, Pule MA, Peggs KS. Roddie C, et al. Among authors: marzolini mav. J Clin Oncol. 2021 Oct 20;39(30):3352-3363. doi: 10.1200/JCO.21.00917. Epub 2021 Aug 31. J Clin Oncol. 2021. PMID: 34464155 Free PMC article. Clinical Trial.
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report.
Mackenzie S, Shafat M, Roddy H, Hyare H, Neill L, Marzolini MAV, Gilhooley M, Marafioti T, Kara E, Sanchez E, Rees J, Lynch DS, Thomson K, Ardeshna KM, Laurence A, Peggs KS, O'Reilly M, Roddie C. Mackenzie S, et al. Among authors: marzolini mav. EJHaem. 2021 Aug 4;2(4):848-853. doi: 10.1002/jha2.274. eCollection 2021 Nov. EJHaem. 2021. PMID: 35845220 Free PMC article.
20 results